The cancer test maker is growing earnings much faster than revenue.
News & Analysis: Genomic Health
GHDX earnings call for the period ending December 31, 2018.
The group rebounded after a terrible end to 2018, but each has big plans for the year ahead.
Inject a little above-average wealth-building potential into your portfolio with any -- or all -- of these three stocks.
Three short years ago, Myriad Genetics was the undisputed leader of the genetic testing industry. A persistent competitor just challenged the diagnostic company -- and a second one is nipping at its heels.
Record revenue and profits lead management to increase 2018 guidance.
The genetic-testing leader kept up its impressive streak of profitable growth during the third quarter of 2018. It now expects earnings several times higher than previous estimates.
GHDX earnings call for the period ending September 30, 2018.
The genetic testing leader's year-to-date momentum continued for yet another month. Should investors be concerned by the streak's abrupt end in October?
The CEO sees steady growth as the company increases volume of its cancer tests and improves reimbursement from payers.